Fluorescence polarization assay for inhibitors of the kinase domain of receptor interacting protein 1 by Maki, Jenny L. et al.
Fluorescence polarization assay for inhibitors of the kinase
domain of receptor interacting protein 1
Jenny L. Makia,1, Elizabeth E. Smitha,1, Xin Tengb, Soumya S. Rayc, Gregory D. Cunyb,d,
and Alexei Degtereva,#
aDepartment of Biochemistry, School of Medicine, Tufts University, Boston, MA 02111
bLaboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham
& Women’s Hospital and Harvard Medical School, Cambridge, MA 02139
cCenter for Neurologic Diseases, Department of Neurology, Brigham & Women’s Hospital and
Harvard Medical School, Cambridge, MA 02139
Abstract
Necrotic cell death is prevalent in many different pathologic disease states and in traumatic injury.
Necroptosis is a form of necrosis that stems from specific signaling pathways with the key
regulator being RIP1, a serine/threonine kinase. Specific inhibitors of RIP1, termed necrostatins,
are potent inhibitors of necroptosis. Necrostatins are structurally distinct from one another yet still
possess the ability to inhibit RIP1 kinase activity. To further understand the differences in the
binding of the various necrostatins to RIP1 and to develop a robust HTS assay, which can be used
to identify new classes of RIP1 inhibitors, we synthesized fluorescein-derivatives of Necrostatin-1
(Nec-1) and Necrostatin-3 (Nec-3). These compounds were used to establish a fluorescence
polarization (FP) assay to directly measure the binding of necrostatins to RIP1 kinase. The
fluorescein-labeled compounds are well suited for HTS since the assays have a DMSO tolerance
up to 5% and Z' scores of 0.62 (fluorescein-Nec-1) and 0.57 (fluorescein-Nec-3). Additionally,
results obtained from the FP assays and ligand docking studies provide insights into the putative
binding sites of Nec-1, Nec-3, and Nec-4.
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Introduction
Necrosis is a major component of pathologic tissue injury in ischemic brain and retinal
damage, heart ischemia/reperfusion injury, intestinal inflammation and brain trauma [1,2].
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The traditional view has been that necrosis is a nonspecific form of cell death caused by
overwhelming stress. However, several recent studies have demonstrated that the activation
of specific signaling pathways in the cell will result in cellular necrosis [3,4,5]. Programmed
necrosis or necroptosis is a regulated caspase-independent form of cell death [6].
Necroptosis can be stimulated in a variety of cells by ligands (TNFα, Fas ligand, TRAIL) of
death domain receptors when apoptosis is blocked or unavailable [7]. Although apoptosis
and necrosis share similar activating stimuli, the outcome of the signaling is different forms
of cell death [6]. The signaling mechanism of apoptosis has been well characterized but the
mechanisms of necroptosis are just starting to be understood. Importantly, the kinase activity
of receptor interacting protein 1 (RIP1) has emerged as a key inducer of necroptosis in a
variety of in vitro and in vivo contexts.
RIP1 is a serine/threonine kinase that belongs to the RIP family of kinases. Two family
members, RIP1 and RIP3, have been identified as components of TNF superfamily receptor
signaling complexes and linked to the induction of necroptosis [8]. RIP1 consists of an N-
terminal kinase domain, an intermediate domain, a RIP homotypic interaction motif
(RHIM), and a C-terminal death domain [9]. In TNF-induced signaling RIP1 is recruited to
the membrane-associated complex I and is K63 polyubiquitinated for NF-κB activation and
cell survival. If cellular conditions are not optimal for survival, complex I releases RIP1 to
form a cytosolic death-initiating signaling complex (DISC), which is also referred to as
complex II. In addition to RIP1, complex II includes RIP3, TRADD, FADD, and caspase-8.
In apoptotic signaling, caspase-8 may cleave de-ubiquitinase CYLD, RIP1 and RIP3,
blocking initiation of necroptosis. However, if caspase-8 is inhibited then cells are trigged to
undergo RIP1/RIP3 kinase-dependent necroptosis [6]. Although RIP1 is part of the complex
in all three cell fates, NF-κB activation, apoptosis, and necroptosis, the kinase activity of
RIP1 has been shown to be required primarily for TNF-induced necroptosis [10] and a
limited number of specific instances of apoptotic death, i.e. induced by certain Toll-like
receptor ligands and DNA damaging agents [11]. The kinase activity of RIP1 can be
specifically inhibited by a series of small molecules termed necrostatins [10,12,13].
Necrostatins were discovered in a cell based screen to find inhibitors of death receptor
mediated necroptosis. One of the hits from this screen was termed necrostatin-1 (Nec-1)
[14]. This hydantoin-containing indole derivative (Figure 1, 1) was optimized to yield a
more potent inhibitor of necroptosis and RIP1 kinase activity (Figure 1, 3) [15,16]. Two
other structurally distinct inhibitor classes were also identified in the original screen [14],
and then optimized resulting in a tricyclic derivative termed Nec-3 (Figure 1, 7) [13] and
[1,2,3]thiadiazole derivative Nec-4 (Figure 1, 9) [12].
In this study, we synthesized two fluorescein-labeled necrostatins (Figure 2, 20 and Figure
3, 26) for the development and optimization of a high-throughput fluorescence polarization
(FP) assay for understanding the binding of different necrostatins to RIP1 kinase and for use
in screening for new inhibitors. Both fluorescein-labeled necrostatins inhibit RIP1 kinase
activity and demonstrate binding in the FP assay. We utilized competitions assays to
determine the specificity of fluorescein-labeled compounds and in conjunction with ligand
docking studies to understand the differences in binding modes between the structurally
different necrostatins. Finally, the feasibility of these assays for HTS was tested with DMSO
tolerance up to 5% and with Z' scores of 0.62 (fluorescein-Nec-1, Figure 2, 20) and 0.57
(fluorescein-Nec-3, Figure 3, 26). These assays are well suited for HTS enabling
identification of novel inhibitors of RIP1 kinase as well as providing valuable tools for
comparing modes of action of different necrostatins.
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Materials and Methods
Reagents and chemicals
All chemicals and reagents were obtained from Sigma, Fisher, or VWR unless otherwise
indicated.
Homology modeling and ligand docking
Induced fit docking: Glide 4.5 [17,18,19] was used for all docking calculations of both
DLG-in and DLG-out structures of RIP1. Induced fit docking protocol with a softened-
potential docking was performed to generate 20 initial poses. The softened-potential docking
consisted of scaling the van der Waals radii by 0.5 except in the event when alanine
substitutions were introduced, in which case the receptor scaling was set to 0.7. In this case
Lys 24, Val 55 and Leu 136 were mutated to alanine to enhance the hit rate of poses in the
initial docking that are close to the correct answer, the Glide hydrogen bond energy cutoff
filter was decreased to −0.05 kcal/mol. This ensures that all retained poses contain at the
very least a weak hydrogen bond with the receptor with backbone amide of Met 74. Second,
the Glide Coulomb-vdW energy cutoff filter was increased to 10 kcal/mol, enabling
toleration of more steric clashes than in a normal docking run. Poses with an RMSD of less
than 0.5 Å and a maximum atomic displacement of less than 1.2 Å were eliminated as
redundant in order to increase diversity in the retained ligand poses. An inner grid box of 10
Å was used to fit the ligand center and an outer box size of 20 Å was used.
For each of the top 20 poses (with respect to GlideScore) from the initial softened-potential
docking step, a full cycle of protein refinement was performed. Prime uses the OPLS-AA
parameter and a surface Generalized Born implicit solvent model. First, a list was generated
consisting of all residues having at least one atom within 5 Å of an atom in any of the 20
ligand poses. All side chains in the list underwent a conformational search and
minimization. Three residues that were mutated to alanine in the initial docking stage were
returned to their original identity prior to the search. After convergence to a low-energy
solution, an additional minimization was performed allowing all residues in the list
(backbone and side chain) and the ligand to be relaxed. The complexes were ranked by
Prime energy (molecular mechanics plus solvation) and those within 30 kcal/mol of the
minimum energy structure were passed through for a final round of Glide docking and
scoring.
The minimized ligand used in the first docking step is redocked using Glide with default
settings into each of the 10 receptor structures produced in protein refinement step. A
composite score that accounts for the protein/ligand interaction energy (GlideScore) [18,19]
and the total energy of the system (Prime energy) is calculated using the following equation:
(GlideScore) + (0.05 × PrimeEnergy).
The RIP1 kinase domain, between residues 17–285, was modeled using MODELLER
[20,21,22]. Briefly, the main criteria in homology modeling were template selection and
sequence alignment between the target and the template. The structure of Aurora kinase
(>30% identity) was used for homology modeling since this enzyme has higher sequence
conservation around the active site region to RIP1 than other kinases. The Cα RMSD and
the backbone RMSD deviations for the model and the template crystal structure were < 1.0
Å and < 1.2 Å respectively. The best model was subjected to geometric evaluations using
PROCHECK [23] with an overall G-value of −0.05. Ramachandran plots indicated that
>93% of the residues are in the allowed region of the map [23,24]. Standard bond lengths
and bond angles of the model were determined using WHAT IF [25] with an RMS-Z score
of 0.8 and 0.9 suggesting that the model is of high quality [26].
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The DLG-out conformation of the kinase was generated using PRIME [27] (Schrödinger
Inc.). Briefly, loop conformation was sampled with the PRIME extended sampling settings.
Side chains within 7.5Å of all residues remained flexible and all structures within a 50 kcal/
mol energy window were saved. PRIME uses a hierarchal approach where the two major
steps are dihedral angle sampling of the backbone to generate possible loop conformations
(no steric clashes with other protein parts or inhibitors is ensured) followed by side-chain
optimization of loop structures further chosen for optimization. The algorithm for side-chain
optimization uses sampling from a highly detailed (10° resolution) rotamer library
constructed by Xiang and Honig from a database of 297 proteins [28]. The final model was
subject to MD thermalization to determine if it was a stable structure. In the thermalization
scheme (simulated annealing), MD simulations of both the DLG-in and DLG-out out
conformations of RIP1 described above were carried out using the DESMOND 3.0 (D.E
Shaw Research and Schrödinger Inc.) [29,30] and the OPLS-AA 2005 force field [31].
Water solvation was described by immersion of the DLG-in (closed) and DLG-out (open)
structures in 26,000 TIP3P waters. Electroneutrality was ensured by adding three Na+ ions
to the system. Periodic boundary conditions and the particle mesh Ewald (PME) method (to
account for long-range electrostatic interactions) were used throughout. Bonds involving
hydrogens were constrained using the M-SHAKE algorithm and a time step integration of
2fs were used for all simulations. A steepest-descent minimization and thermalization
scheme was applied to all of the initial structures. The systems were heated from 0 to 300 K
in 200ps, keeping the Cα atoms fixed in their original positions. In the next step, all of the
constraints were lifted, and the equilibration was continued in the isobaric–isothermal
ensemble with Nose–Hoover thermostats for 1.0 ns.
Docking of Nec-1, Nec-3 and Nec-4 was performed using GLIDE v2.2 (Schrödinger Inc.)
[17,18,19]. A 10Å search grid was used using the center of mass of P-loop and the activation
loop as the point of origin. A hydrogen bond constraint was placed on backbone amide of
M95. This reduced random conformation search significantly while docking. GLIDE
docking was carried out in standard precision (SP) mode and at least 10 poses were
requested with a docking score cutoff of −7.0 (anything lower than −7.0 was treated as a
hit). The poses were inspected in Maestro 9.2 and selected for further analysis.
Synthesis of Nec-1 benzyl substituted analogs
Compound 10 was made according to our previous publication [15] by regioselective
alkylation of the hydantoin with various benzyl bromides under basic conditions (Figure
2A).
Cellular EC50 determination of necrostatins
EC50 values of Rac-3, 4, 5, 6, and 7 were determined using CellTiter-Glo (Promega)
luminescent cell viability assay as previously described [15,16].
Plasmid construction of GST-RIP1 kinase domain
The human RIP1 kinase domain (aa 8–327) was amplified by PCR using Phusion High-
Fidelity Polymerase (New England Biolabs), digested with EcoRI and PstI restriction
enzymes (New England Biolabs), and ligated into the same sites in the pAcGHLT-A
Baculovirus Transfer Vector (BD Biosciences) creating the pAcGHLT-A-GST-hRIP1 8–
327 plasmid. DNA sequencing (Core Facility, Tufts University) verified the correct
sequence of the plasmid.
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Protein expression and purification GST-RIP1 kinase domain fusion
Spodoptera frugiperda (Sf9) insect cells were grown in Sf-900 II SFM medium (Gibco/
Invitrogen) at 27°C. To generate the GST-RIP1 baculovirus, 2 µg of pAcGHLT-A-GST-
hRIP1 8–327 and 0.5 µg of linearized BaculoGold Bright DNA (BD Biosciences) were
transfected into Sf9 cells using the BD BaculoGold Transfection Buffer A & B Set (BD
Biosciences) according to the manufacturer’s protocol and virus was amplified to passage
four. For protein expression, Sf9 cells were grown in ESF921 Protein Free medium
(Expression Systems) by shaking (150 rpm/min) at 27°C to a density of 3×106 cells/ml and
infected with passage four baculovirus to express GST-hRIP1 8–327 recombinant protein.
Five days after infection the cells were harvested and resuspended in lysis buffer (40 mM
HEPES pH 7.3, 150 mM NaCl, 5 mM EDTA, 0.5 mM NaF, 0.2 mM NaVO3, 10 mM
sodium pyrophosphate, 17.5 mM β-glycerolphosphate, 1 µg/ml aprotonin, 1 µg/ml leupeptin,
1 µg/ml pepstatin, 50 µg/ml PMSF). Cells were disrupted using a sonicator followed by
centrifugation. Protein was purified using a 5 ml Glutathione 4B sepharose (GE Healthcare)
column. GST-RIP1 fractions were combined, concentrated to ~1 ml, and injected onto a
Superdex 200 10/300 GL Column (GE Healthcare Life Sciences). The protein was eluted
using an isocratic gradient (50 mM Tris pH 8.0, 150 mM NaCl, 2 mM β-mercaptoethanol)
for 1.5 column volumes and pure GST-RIP1 fractions were pooled and concentrated. Both
20% glycerol and 1 mM PMSF were added to the protein followed by flash freezing and
storage at −80°C. The final protein concentration was determined using a NanoDrop 2000
Spectrophotometer (Thermo Scientific).
Radiometric Gel Kinase Assay
The assay was performed as described [10] with minor modifications. In kinase buffer (20
mM HEPES pH 7.3, 10 mM MnCl2, 10 mM MgCl2) 2 µM GST-RIP1 protein was
preincubated with various concentrations of compounds for 10 minutes. Stock compounds in
DMSO were further diluted with DMSO to the appropriate concentration and added to the
reaction for a final DMSO concentration of 3% in all samples. The kinase reaction was
initiated with the addition of 30 µM cold ATP and 3 µCi of [γ-32P] ATP (Perkin Elmer) and
incubated at 30°C for 30 min shaking at 600 rpm. Reaction were quenched by the addition
of SDS-PAGE sample buffer and immediately boiled. The samples were run on a 15% SDS-
PAGE gel and dried. Autophosphorylation of GST-RIP1 was visualized by gel exposure to
x-ray film.
Synthesis of fluorescien-labeled necrostatins
The fluorescein analog of Nec-1 was prepared using the methodology outlined in Figure 2E.
Phenol 12 was converted to triflate 13, which in the presence of a Pd catalyst and zinc
cyanide was transformed into 14 [32]. Bromination of this material gave 15 [33] 7-
Chloroindole (16) was converted to 17a and then to 17b [34]. The nitrile was subsequently
reduced to aldehyde 17c, which was transformed to hydantoin 18 [15]. Regioselective
alkylation of 18 with 15 gave 6. Reduction of this nitrile generated 19, which in the presence
of FITC yielded the fluorescein-labeled Nec-1 derivative 20. The final compound was
verified by 1H NMR (Supplemental Materials and Methods).
The fluorescein analog of Nec-3 was prepared using the methodology outlined in Figure 3A.
Condensation of 21 and 22 give the chalcone 23. Cyclization in the presence of hydrazine
followed by acylation provided 24 (and its diastereomer, which was readily separated). Ester
hydrolysis followed by HBTU-mediated coupling of N-Boc piperazine gave 25. This
material was de-protected with trifluoroacetic acid (TFA) and the resulting amine was
coupled with FITC to give the fluorescein-labeled Nec-3 derivative 26. The final compound
was verified by 1H NMR (Supplemental Materials and Methods).
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General FP Methods
All FP experiments were conducted in 384-well, low volume, non-treated, round bottom,
black polystyrene microplates (Corning 3677) and read using a Victor3V 1420 Multilabel
Counter (PerkinElmer). Polarization values are reported in millipolarization units (mP) and
were determined using an excitation wavelength of 485 nm (15 nm bandwidth) and an
emission wavelength of 535 nm (25 nm bandwidth) with a count time of 1 sec and a G-
factor of 1.4.
Estimation of KD values of fluorescent necrostatins binding to GST-RIP1 kinase domain
To each well was added: 1 µl of 750 nM 20 (50 mM Tris pH 8.0, 20% glycerol, 5 mM
MgCl2, 5 mM MnCl2), 12.15 µl of increasing concentration (0 to 100 µM) of GST-RIP1 (50
mM Tris pH 8.0, 150 mM NaCl, 20% glycerol), 1.35 µl of 5X kinase buffer (100 mM
HEPES pH 7.3, 50 mM MgCl2, 50 mM MnCl2), and 0.5 µl of DMSO. FP measurements
were taken after a 10-minute incubation. The KD of 20 was calculated using nonlinear
regression one-site binding model (GraphPad Prism 5). The same procedure was used to
calculate the KD of 26.
Estimation of IC50 and Ki values for unlabeled necrostatins
To each well, 50 nM of 20 was added to 2.6 µM of GST-RIP1 kinase domain and incubated
for 5 minutes. Increasing concentrations of unlabeled compounds (0 to 100 µM) were added
to the reaction with a final DMSO concentration of 3%. FP measurements were taken after a
10-minute incubation. The IC50 values were determined using nonlinear, variable slope
fitting (GraphPad Prism 5). The Ki values were determined using the equation described by
Nikolovska-Coleska et al. [35]. The same procedure was used with 50 nM of 26 and to 3.4
µM of GST-RIP1 kinase domain to calculate the IC50 and Ki values.
DMSO tolerance
Increasing concentrations of DMSO, 0–10% of the assay volume, were used to measure mP
of 20 and mP of 20 with 2.6 µM of GST-RIP1. FP measurements were taken after 10-minute
incubation. The same procedure was used with 26 and 26 with 3.4 µM of GST-RIP1 kinase
domain.
Z' determination
To verify the assay for high throughput screening, the Z factor was calculated using the
following equation: Z'=1− ((3σp + 3σn)/|μp − μn|) which was initially described in Zhang et
al. [36]. σp and σn are the standard deviations of GST-RIP1/20 and GST-RIP1/20/Rac-3
respectively; whereas μp and μn are the averages. The following concentrations were used:
2.6 µM GST-RIP1, 50 nM 20, and 50 µM Rac-3. Three independent experiments for each
were combined and averaged. The procedure was used for 50 nM 26, 3.4 µM GST-RIP1 and
50 µM 7.
Result and Discussion
Development of fluorescein-labeled necrostatins
Our previous work revealed that the structurally dissimilar necrostatins, Nec-1, Nec-3 and
Nec-4, (Figure 1A, 1, 7, 9) all specifically target RIP1 kinase activity at sub-micromolar
concentrations [10] and remain the only reported inhibitors of this kinase. Surprisingly, our
previous data also suggests that each distinct necrostatin may have a different mode of RIP1
inhibition [10,13]. Given the emerging importance of necroptosis in numerous pathologic
injuries and the widespread use of necrostatins to dissect the role of RIP1 kinase in vitro
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[37,38,39,40] and in vivo [41,42,43,44,45,46], a better understanding of necrostatins’ mode
of action is critical for therapeutic development as well as in the identification of new
classes of RIP1 inhibitors. In particular, new assays to directly measure the binding of
structurally distinct necrostatins to RIP1 kinase will help guide new inhibitor development.
In our previous study using a cell-based necroptosis assay [15], we discovered that Nec-1
(Figure 1A, 1) inhibitory activity was intolerant to substitution at several positions on the
indole ring as well as many positions on the hydantoin ring. Despite the sensitivity to
structural modification, the structure-activity relationship (SAR) study on Nec-1 enabled us
to make an optimized version (3) but further modifications proved difficult. We re-examined
the molecular model of RIP1/Nec-1 complex [10] using induced fit ligand docking to
determine if Nec-1 preferentially bound the DLG-out or DLG-in conformation of RIP1. As
our previous work suggested [10], Nec-1 interacted better with the DLG-out conformation.
Therefore, we used this information to help guide the synthesis of a fluorescein-Nec-1
analog. According to our model (Figure 1B), the methyl group of hydantoin is positioned
between the hinge and the N-terminal region of RIP1. The SAR study [15] demonstrated
that replacement of the methyl on the hydantoin with an isopropyl group was not tolerated.
This can be explained in the RIP1 molecular model by steric clashes between isopropyl and
the side chains of L23 in the P-loop and various residues in the hinge, which are
approximately 4–5 Å away from the carbon of the methyl group. However, the addition of a
longer linker could allow for further modification to this position on the hydantoin.
To help determine if the addition of a longer linker attached to bulky hydrophobic
fluorescein isothiourea group onto a N-benzyl substituted Nec-1 (i.e. Figure 2E, 20) would
potentially have an impact on binding to RIP1, we used the induced fit docking model of
Nec-1 with fluorescein attached (Figure 1C, S1). In this model, the Nec-1 portion of 20 is
making extensive contacts inside of the ATP binding pocket, while the addition of the a N-
benzyl substituted linker projects the fluorescein group outside of the binding pocket and
into the solvent making few if any molecular contacts with RIP1.
Using the docking study as a guide, we first synthesized Nec-1 intermediate analogs with
various benzyl substituents on the hydantoin ring (4, 5, 6, and Figure 2A) to determine if a
longer linker would retain inhibitory activity. These intermediate analogs were tested in a
necroptosis cell viability assay (Figure 2B) as well as in a radiometric in-vitro kinase assay
using recombinant GST-RIP1 (Figure 2C). Optimized racemic Nec-1 (Rac-3) has an EC50
of 180 nM in the cell-based necroptosis assay, while the addition of the benzyl on the
hydantoin ring (4) caused an increase in the EC50 value to 748 nM. The chloro (5) and
chloro/cyano (6) substitutions have only a slight difference in EC50 values, 220 nM and 420
nM respectively, from Rac-3 (Figure 2B). The in-vitro kinase assay demonstrated that all of
the inhibitors decreased the autophosphorylation of GST-RIP1 with the benzyl substituted
compounds, 4, 5, and 6, having a slight decrease in potency when compared to Rac-3
(Figure 2C). These results suggest that addition of a benzyl group to the imide nitrogen of
the hydantoin ring retains significant activity and provides a new direction for further Nec-1
derivatization.
Since our docking model suggested that addition of fluorescein to the benzyl linker would
not significantly impact binding, we developed a method to synthesize a fluorescein-Nec-1
analog (20, Figure 2E). This compound was tested in the in-vitro kinase assay and inhibited
the autophosphorylation of GST-RIP1 comparable to Rac-3, while the inactive Nec-1
analog 2 did not inhibit activity (Figure 2D). Compound 20 displayed an excitation
maximum at 490 nm and an emission maximum at 515 nm, consistent with the spectrum of
fluorescein. The values of perpendicular and parallel fluorescence of 20 substantially
exceeded the background of buffer alone under the assay conditions (Figure S2). Therefore,
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even though our previous data suggested a very restricted SAR of Nec-1[15], modification
of the hydantoin nitrogen allowed us to successfully synthesize a fluorescent Nec-1 analog
that retained inhibitory potency and possessed fluorescent properties needed for FP assay.
In addition to the synthesis of fluorescent Nec-1 analog 20, we also attempted to develop a
fluorescein-labeled analog of Nec-3, 7. Using our previous SAR data for this compound
series [13], we added a piperazine containing linker at the N1-position terminating in a
fluorescein group resulting in compound 26 (Figure 3A). This new compound was also able
to inhibit autophosphorylation of GST-RIP1 in the in-vitro kinase assay (Figure 3B), similar
to the fluorescent Nec-1 analog. Similar to 20, compound 26 also displayed excitation/
emission maxima at 495 and 515 nm, respectively, and robust signal to background ratios
were observed under the assay conditions (Figure S2).
KD determination of fluorescent-Nec analogs in FP assay
To test the binding capabilities of 20 and 26 in FP assays, the GST-RIP1 kinase domain
protein was titrated into 50 nM 20 and 50 nM 26 (Figure 4). In both cases, we observed a
dose-dependent increase in polarization indicative of binding. We fit the curves to determine
KD values for compounds 20 (2.6 ± 0.3 µM) and 26 (3.4 ± 0.5 µM). These low micromolar
KD values are in good concert with somewhat reduced activity of fluorescent analogs
observed in 32P assays when compared to parental Nec-1 and Nec-3 (Figures 2D and 3B),
which display sub-micromolar activities in the cell based assays [10].
Competitive binding experiments using FP assay
To ensure that the binding of 20 is specific and reversible, we performed competition assays
with the Nec-1 intermediate analogs, 4, 5, and 6 (Figure 5A). As expected, these compounds
were able to compete with 20 with comparable Ki values (Table 1) to the 2.6 ± 0.3 µM KD
for 20. The rank order of the Ki values of the intermediate analogs was the same as their
activities in a cell viability assay (Figure 2B). Therefore, we continued our characterization
by testing 20 in competition assays with 1, Rac-3, the optimized R-enantiomer (R-3), and
inactive compound 2 (Figure 5B). Rac-3, R-3, 1 were able to displace 20 from GST-RIP1
with the rank order of R-3, Rac-3, 1 (Table 1) the same as we saw in the cell based SAR
study [15]. The inactive analog did not compete with 20 demonstrating the specificity of this
assay. Overall, these data confirm that we are measuring specific binding of Nec-1 to RIP1
kinase and the competition assays reflect the affinities of Nec-1 analogs to RIP1 kinase.
Since 20 is specific and reversible in binding to GST-RIP1, we tried cross-competition
titrations with Nec-3 (7) and Nec-4 (9) to understand if there are differences in the binding
mode of these structurally different necrostatins. Both compounds 7 and 9 are able to
compete with 20 for binding to GST-RIP1 (Figure 5C). At the same time, differences, albeit
subtle, could also be detected. Compound 9 is a slightly better competitor than 7 with a
lower Ki value (Table 1) that is similar to R-3. Although 7 displayed similar potency to
Rac-3 in the cell viability assay (Figure 2B), 7 was a modestly weaker competitor with 20 in
the FP assay. Our previous data suggests that Nec-1 is ATP competitive [10] and docks into
the ATP binding pocket of the DLG-out conformation of RIP1 (Figure 1B). Therefore, the
cross-competition data revealed that even though Nec-1 and Nec-4 are structurally very
different, these molecules share overlapping binding sites. It is probable that Nec-3 is also
binding close to the ATP binding site but at a region somewhat distal to Nec-1.
We also tested compound 26 for specificity by conducting competition titrations with Nec-3
(7) and its inactive analog, Nec-3i (8) [10] (Figure 5D). As seen with compound 20, 7 is able
to compete with 26 for binding to GST-RIP1, while 8 does not compete. As with 20, 26
displayed a moderately decreased binding affinity for GST-RIP1 compared to the parental
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compound (0.76 ± 0.21 µM Ki of 7 versus 3.4 ± 0.5 µM KD of 26), likely indicating some
hindrance from the linker/fluorescein groups. We also tested 26 in cross-competition assays
with Rac-3 and 9 (Figure 5E). Compound 9 was again a slightly better competitor than
Rac-3 with Ki and IC50 values comparable to 7 (Table 2). Overall, all three compounds
cross-compete with each other but compound 9 is able to more effectively displace both 20
and 26 in comparison to the parent compounds Rac-3 and 7, respectively. This suggests that
Nec-4 binding likely significantly overlaps with both the Nec-1 and the Nec-3 binding sites.
Conversely, since Nec-1 and Nec-3 compete less strongly with each other, they may only
have moderate overlap in binding sites. Altogether, these results establish a new FP based
necrostatin/RIP1 assay, which provides a rapid and robust method for comparing binding
modes of different classes of RIP1 kinase inhibitors.
To further understand the binding sites of the different necrostatins, we pursued more
docking studies with RIP1. The induced fit docking of 3 demonstrated a strong preference
for the DLG-out conformation. This conformation places the indole of 3 in the pocket where
the adenine of ATP likely binds and the hydantoin is positioned between the hinge and the
N-terminal domain/P-loop (Figure 1B, S3A). We generated a ligand interaction diagram to
further understand the nature of the Nec-1 binding pocket (Figure S3B). The pocket has both
hydrophobic character and a key hydrogen bond that is typically found in active site kinase
inhibitors [47]. Additional docking studies with 7 revealed that Nec-3 could dock into both
DLG conformations in a similar manner but prefers the DLG-in form. To compare to the
Nec-1 binding site we used the DLG-out docking and discovered that compound 7 makes
significant contacts with the hinge and C-terminal domain immediately following the hinge
(Figure S4). This conformation of 7 would position the fluorescein group of 26 out towards
solvent near the C-terminal domain. The nature of the pocket is predominately hydrophobic
with the potential for form stacking interactions. Placing both 3 and 7 together in the DLG-
out conformation indicates that they have different but partially overlapping binding sites
(Figure 6B). The fused benzene ring portion of 7 binds to the same region as the hydantoin
of 3 but has no significant overlap with the indole. This is in agreement with our FP
competition results, which indicated that 3 and 7 compete with each other weakly likely due
to partially overlapping binding sites. Compound 9 also docked in both DLG-out and DLG-
in conformations of RIP1 but to understand the competitions with 3 and 7, we used the
DLG-out docking. The docking revealed that 9 contacts both the adenine binding pocket and
the hinge (Figure S5). The interactions in the pocket are mostly hydrophobic but also
involve two hydrogen bonds. This binding orientation would disrupt hydantoin binding of 3
and potentially cause steric clashes with the indole ring (Figure 6C). Compound 9 binds in a
similar manner as 7 with all interaction being disrupted except for the pendent
methoxyphenyl (Figure 6D). These docking studies support our results from the FP
competition studies where 9 competes strongly with both 3 and 7, while 3 and 7 compete but
to a lesser degree.
Feasibility of FP assay for HTS
In order to validate the use of both 20 and 26 for HTS FP assays, we performed DMSO
tolerance and Z'-score analysis. DMSO is a solvent generally used to dissolve small
molecules used in screening assays. Therefore, we tested our FP assay to determine the
usable range of DMSO, which itself does not have an effect on the polarization of either 20
or 26 (Figure 7A,C). Binding of both fluorescent molecules to GST-RIP1 was reduced by
<30% at DMSO concentrations of up to 5%, establishing the tolerated range for DMSO
between 0 and 5%.
We further analyzed compounds 20 and 26 in Z'-score analysis. In this case we used the
fluorescent compound/GST-RIP1 as the positive control and the fluorescent compound/
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GST-RIP1/non-fluorescent parent compound as the negative control. For compound 20 Z' is
0.62, while for compound 26 Z' is 0.57 (Figure 7B,D). Both of these compounds are well
suited for future use in HTS-FP assays for the identification and development of RIP1
inhibitors.
In summary, we have identified new directions for Nec-1 and Nec-3 modification and
developed two fluorescein-labeled necrostatins that specifically and reversibly bind to RIP1.
Both of these molecules are well suited for use in HTS-FP assays, providing a simple and
robust homogeneous assay for the identification of new RIP1 inhibitors. We also discovered
that Nec-1 (3), Nec-3 (7), and Nec-4 (9) are able to cross-compete with each but to varying
degrees. First, these data along with our docking studies indicate that all three structurally
distinct necrostatins interact with the active center of RIP1 kinase through overlapping
binding sites. Second, Nec-4 is able to effectively compete with both Nec-1 and Nec-3 and
our docking results are consistent with the model in which Nec-4 binding site overlaps with
both Nec-1 and Nec-3. On the other hand, Nec-1 and Nec-3 occupy more distinct, less
overlapping binding sites. Further structural studies are required to characterize the
conformations of RIP1 kinase preferred by Nec-3 and Nec-4 as our docking analysis
suggested that these molecules may interact with both DLG-out and DLG-in conformations.
This will define whether these molecules are acting as allosteric inhibitors in a binding mode
different from Nec-1. Furthermore, our data suggest that using both fluorescent-Nec-1 and
fluorescent-Nec-3 in primary or secondary assays will provide a simple and robust method
to assess RIP1 binding modes of new molecules allowing for the selection of molecules
distinct from the currently available classes of necrostatins.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
(A) Structures of the different necrostatins. (B) Induced fit docking model of Nec-1-RIP1.
Nec-1 (3) was docked into the molecular model of RIP1 kinase domain (aa 22–291) as
described in the Materials and Methods. RIP1 is shown as a cartoon with the N-terminal
domain in cyan, P-loop in blue, hinge in magenta, DLG in black, activation segment in
orange, and C-terminal domain in green with 3 shown as sticks in red. (C) A surface
representation zoomed in to the ATP-binding region of RIP1 is shown with Nec-1 and
fluorescein portions of 20 labeled. Different views of this complex are shown in Figure S1.
The model of RIP1/20 complex indicates that fluorescein does not interact with RIP1. RIP1
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is color-coded as described in B and 20 is color-coded by element: carbon in yellow,
nitrogen in blue, and oxygen in red. Images were made using PyMol.
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Figure 2.
(A) Synthesis of Nec-1 derivatives 4, 5, and 6. Compound 10 was made as previously
described [15]. a) various benzyl bromide, KOH, EtOH/H2O, 95°C, 14h. (B) The dose-
response curves of optimized racemic Nec-1 (Rac-3), intermediate analogs (4, 5, 6), and
Nec-3 (7) in a necroptosis cell-based assay as previously described [14] [15]. Viability was
normalized to cells treated with DMSO. (C) In vitro kinase assay of Nec-1 intermediate
analogs. The autophosphorylation of recombinant GST-RIP1 was performed as indicated in
the Materials and Methods. Samples were run on SDS-PAGE gel and autophosphorylation
was visualized by autoradiography. D is the DMSO control sample while the concentrations
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of Nec-1 analogs are shown above the gel. (D) In vitro kinase assay with the Rac-3, 20, and
inactive Nec-1 (2). Compound 20 is able to inhibit the autophosphorylation activity of GST-
RIP1. (E) Synthesis of Nec-1 fluorescein derivative. a) triflic anhydride, Py, CH2Cl2, 0°C,
6h; b) Zn(CN)2, Pd(PPh3)4, DMF, 60°C, 14h; c) NBS, AIBN, CCl4, reflux, 12h; d) N,N-
dimethylmethylene ammonium chloride, CH2Cl2, rt, 2h, then 1M NaOH; e) NaCN, EtOAc,
DMSO, 80°C, 6h; f) DIBAL, toluene, −78°C to rt, 2h; g) (NH4)2CO3, KCN, EtOH, H2O,
60°C, 14h; h) 15, KOH, EtOH/H2O, 95°C, 8h; i) H2, Raney Ni, NH3 in MeOH, 6h; j)
fluorescein isothiocyanate (FITC), DMF, 0°C to rt, 1h.
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Figure 3.
(A) Synthesis of Nec-3 fluorescein derivative. a) NaOH, EtOH, H2O, rt, 2h; b)
(CH3)3CCOOH, hydrazine hydrate, EtOH, 120°C, reflux, 16h; c) Methyl 10-chloro-10-
oxodecanoate, sat. aq. NaHCO3, EtOAc, 2h; d) NaOH, MeOH, 6h; e) N-Boc-piperazine,
HBTU, DIPEA, CH2Cl2, rt, 14h; f) TFA, CH2Cl2, rt, 1h; g) FITC, DMF, 0°C to rt, 1h. (B)
In vitro kinase assay with the Nec-3 (7), fluorescein-Nec-3 (26), and inactive Nec-3 (8).
Compound 26 is able to inhibit the autophosphorylation activity of GST-RIP1.
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Figure 4.
KD determination of fluorescent analogs. (A) Increasing concentrations of GST-RIP1
protein were titrated into 20 and the curve was fitted to obtain a KD of 2.6 ± 0.3 µM with a
R2 value of 0.96 and Bmax value of 210 mP. (B) Increasing concentrations of GST-RIP1
protein were titrated into 26 and the curve was fitted to obtain a KD of 3.4 ± 0.5 µM with a
R2 value of 0.96 and Bmax value of 188 mP.
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Figure 5.
Competition Assays with fluorescent analogs. (A) GST-RIP1 and 20 were incubated
together for five minutes and then increasing concentrations of 4, 5, and 6 were titrated.
Curves were fit to determine IC50 and Ki values for each compound (Table 1 and 2). (B)
Competition assays with GST-RIP1/20 and 1, 2, Rac-3, and R-3. (C) Competition assays
with GST-RIP1/20 and Rac-3, 7, and 9. (D) Competition assays with GST-RIP1/26 and 7
and 8. (E) Competition assays with GST-RIP1/26 and Rac-3, 7, and 9.
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Figure 6.
Docking of the necrostatins to RIP1. (A) The induced fit docking model of Nec-1, color-
coded as in Figure 1C, and RIP1 is shown. The residues making the binding pocket for
Nec-1 determined from ligand interaction diagram (Figure S2) are color-coded by amino
acid type: green-hydrophobic, cyan-polar, red-acidic, blue-basic, and glycinetan. The black
dashed line indicates a hydrogen bond. (B) Nec-1 (3) in red and Nec-3 (7) in yellow are
docked into the DLG out conformation of RIP1. The two molecules partially overlap in their
binding sites. (C) Nec-1 (3) in red and Nec-4 (9) in brown docked into the DLG out
conformation of RIP1. The two molecules partially overlap. (D) Nec-3 (7) in yellow and
Nec-4 (9) in brown are docked into the DLG out conformation of RIP1. The two molecules
significantly overlap with each other.
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Figure 7.
Feasibility of FP assay for HTS. (A) DMSO tolerance of 20 in FP was tested with 20 alone
(black bars) and GST-RIP1/20 complex (white bars) in 0–10% DMSO. Concentrations at or
below 5% are well-tolerated in this assay. (B) Z'-score for 20 was tested in three separate
experiments in 10-wells each with GST-RIP1/20 and GST-RIP1/20/Rac-3. The average
from all 30 wells was used to normalize each of the three separate experiments. Z' is 0.62
demonstrating that this is an excellent assay for HTS. (C) Same as in (A) except using 26.
(D) Z'-score for 26 was tested as described in (B) with GST-RIP1/26 and GST-RIP1/26/7. Z'
is 0.57 demonstrating that this is an excellent assay for HTS.
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Table I
Summary of Competition Assays with 20
Compound IC50 (µM) Ki (µM)
4 8.5 ± 1.2 3.4 ± 0.6
5 6.0 ± 0.2 2.1 ± 0.1
6 9.6 ± 0.6 3.9 ± 0.3
1 9.9 ± 0.6 4.1 ± 0.3
R-3 3.6 ± 0.7 0.92 ± 0.36
Rac-3 5.7 ± 1.0 2.0 ± 0.5
7 10.7 ± 1.8 4.5 ± 0.9
9 2.6 ± 0.1 0.46 ± 0.05
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Table 2
Summary of Competition Assays with 26
Compound IC50 (µM) Ki (µM)
7 3.9 ± 0.7 0.76 ± 0.21
1 7.0 ± 0.7 2.4 ± 0.4
9 3.9 ± 0.5 0.80 ± 0.27
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